Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014 competitive analysis - PowerPoint PPT Presentation

About This Presentation
Title:

Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014 competitive analysis

Description:

Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014’, provides an overview of the Prader-Willi Syndrome (PWS)’s therapeutic pipeline. To Get More Info. Visit : This report provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prader-Willi Syndrome (PWS) and special features on late-stage and discontinued projects. – PowerPoint PPT presentation

Number of Views:172

less

Transcript and Presenter's Notes

Title: Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014 competitive analysis


1
Prader-Willi Syndrome (PWS) - Pipeline Review, H2
2014
No. Pages 53
Published on Dec-2014
2
Report Description
Global Markets Directs, Prader-Willi Syndrome
(PWS) - Pipeline Review, H2 2014, provides an
overview of the Prader-Willi Syndrome (PWS)s
therapeutic pipeline.This report provides
comprehensive information on the therapeutic
development for Prader-Willi Syndrome (PWS),
complete with comparative analysis at various
stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of
administration (RoA) and molecule type, along
with latest updates, and featured news and press
releases. It also reviews key players involved in
the therapeutic development for Prader-Willi
Syndrome (PWS) and special features on late-stage
and discontinued projects. To Get More Info.
Visit http//www.analyzefuture.com/prader-willi
-syndrome-pws-pipeline-review-h2-2014-market
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team.
3
Report Description
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. To Enquire
About Report _at_ http//www.analyzefuture.com/prade
r-willi-syndrome-pws-pipeline-review-h2-2014-marke
t/report-enquiry The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products.
4
Table of Content
Table Of ContentsTable of ContentsTable of
Contents 2List of Tables 4List of Figures
4Introduction 5Global Markets Direct Report
Coverage 5Prader-Willi Syndrome (PWS) Overview
6Therapeutics Development 7Pipeline Products
for Prader-Willi Syndrome (PWS) - Overview
7Pipeline Products for Prader-Willi Syndrome
(PWS) - Comparative Analysis 8Prader-Willi
Syndrome (PWS) - Therapeutics under Development
by Companies 9Prader-Willi Syndrome (PWS) -
Pipeline Products Glance 10Late Stage Products
10Clinical Stage Products 11Early Stage
Products 12Prader-Willi Syndrome (PWS) -
Products under Development by Companies
13Prader-Willi Syndrome (PWS) - Companies
Involved in Therapeutics Development 14
5
Table of Content
Chong Kun Dang Pharmaceutical Corp.
14Essentialis, Inc. 15Ferring International
Center S.A. 16LG Life Sciences, Ltd. 17P2D
Bioscience 18Pfizer Inc. 19Rhythm
Pharmaceuticals 20Prader-Willi Syndrome (PWS) -
Therapeutics Assessment 21Assessment by
Monotherapy Products 21Assessment by Target
22Assessment by Mechanism of Action
24Assessment by Route of Administration
26Assessment by Molecule Type 28Drug Profiles
30beloranib - Drug Profile 30Product
Description 30Mechanism of Action 30RD
Progress 30betahistine hydrochloride - Drug
Profile 33
6
Table of Content
Product Description 33Mechanism of Action 33RD
Progress 33diazoxide choline CR - Drug Profile
34Product Description 34Mechanism of Action
34RD Progress 34FE-992097 - Drug Profile
36Product Description 36Mechanism of Action
36RD Progress 36NOX-B11 - Drug Profile
37Product Description 37Mechanism of Action
37RD Progress 37setmelanotide - Drug Profile
38Product Description 38Mechanism of Action
38RD Progress 38
7
Table of Content
somatropin SR - Drug Profile 39Product
Description 39Mechanism of Action 39RD
Progress 39Prader-Willi Syndrome (PWS) - Recent
Pipeline Updates 41Prader-Willi Syndrome (PWS) -
Product Development Milestones 46Featured News
Press Releases 46Nov 14, 2014 Essentialis To
Present Clinical Update At The Annual Research
Conference Of The Foundation For Prader-Willi
Research 46Oct 01, 2014 Zafgen Announces
Initiation of Phase 3 Trial of Beloranib in
Prader-Willi Syndrome 46Jul 23, 2014
Essentialis Secures Foundation for Prader-Willi
Research Grant to Help Advance DCCR in the
Treatment of Prader-Willi Syndrome 47Jul 10,
2014 Zafgen Granted Orphan Drug Designation in
the European Union for Beloranib, a
First-in-Class MetAP2 Inhibitor for the Treatment
of Prader-Willi Syndrome 47 To Get Complete TOC
Visit at http//www.analyzefuture.com/prader
-willi-syndrome-pws-pipeline-review-h2-2014-market
/table-of-contents
8
FOR MORE DETAILS
Visit us at
http//www.analyzefuture.com/
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States.
TELEPHONE 1 (855) 711-1555 EMAIL
sales_at_analyzefuture.com
Write a Comment
User Comments (0)
About PowerShow.com